JPRN-jRCTs031200256招募中2 期
A phase II trial evaluating the efficacy and safety of repeated high dose MPA therapy for patients with recurrent early stage endometrial cancer or atypical endometrial hyperplasia (JGOG2051)
Yamagami Wataru0 个研究点目标入组 115 人开始时间: 2020年12月21日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 115
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 42age 11month old（—）
- 性别
- Female
入选标准
- •1) Patients with atypical endometrial hyperplasia or G1 without myometrial invasion or extrauterine lesions who underwent high-dose MPA therapy for primary lesions or intrauterine recurrence.
- •Recurrence number can be allowed up to 2 times.
- •2) Patients with histologically confirmed endometrial carcinoma Grade 1 or endometrial by recent dilation and curettage.
- •3) Patients without possible myometrial invasion, cervical stromal invasion or extrauterine lesions by pelvic MRI at relapse.
- •4) Patients without possible lymph node or distant metastases by CT imaging of the chest, abdomen and pelvis at relapse.
- •5) Age 20 to 42 years old.
- •6) Patients who hope to preserve fertility.
- •7) ECOG performance status:0-1
- •8) The following tests must be conducted within
- •14 days prior to enrollment:
- •Neutrophils count more than or equal to 1,000/mm3
- •Hemoglobin more than or equal to 9.0g/dL
- •Platelet count more than or equal to 10.0x10000/mm3
- •AST(GOT), ALT(GPT) less than or equal to 100 U/L
- •Serum total bilirubin less than or equal to 2.2mg/dL
- •Serum creatine less than or equal to 1.5mg/dL
- •D-dimer less than or equal to 1.0ug/mL
- •9) Signed informed consent obtained prior to initiation of study-specific procedures and treatment as confirmation of the patient's awareness and willingness to comply with the study requirements.
排除标准
- •1) Patients without recurrent intrauterine lesions histologically diagnosed endometrial carcinoma Grade 1 or atypical hyperplasia.
- •2) Recurrent number more than or equal to 3 (*)
- •3) Patients who have been registered to this trial.
- •4) Patients without pathologically disappeared intrauterine lesions at previous treatment. Pathological disappearance is defined as disappearance of endometrial hyperplasia.
- •5) Patients whose myometrium cannot be diagnosed correctly due to uterine disease (such as endometriosis or leiomyoma)by pelvic MRI
- •6) Patients with a history or evidence of thrombosis
- •7) BMI more than or equal to 45kg/m2
- •8) Patients with a history of hypersensitivity to luteinizing hormone.
- •9) Patients with heart disease (such as valvular heart disease, atrial fibrillation, endocarditis, severe heart failure
- •10) Peripheral neuropathy (motor and/or sensory) of Grade 2 or greater (CTCAE v 5.0).
- •11) Patients with active double/multiple cancer, or double cancer patients with disease free interval of less than 5 years (lesions equivalent to carcinoma in situ is excluded as active double cancer).
- •12) Patients with a history of chemotherapy or radiotherapy.
- •13) Patients with severe hepatic dysfunction.
- •14) Patients with hypercalcemia.
- •15) Patients with poorly controlled diabetes and/or hypertension.
- •16) Patients who cannot undergo MRI and CT.
- •17) Patients who cannot stop other hormone therapy
- •18) Patients who is judged inappropriate to participate in this study by the principle investigator.
- •* If complete response rate of 2-time recurrent patients is clearly poor, the registration of 2-time recurrent patients will be discontinued.
研究者
相似试验
终止
2 期
ANZ 0502 Neoadjuvant Gemcitabinearge operable, or locally advanced breast carcinoma.Large operable, or locally advanced breast carcinoma.Cancer - BreastACTRN12606000191594ANZ Breast Cancer Trials Group Ltd.81
进行中（未招募）
1 期
A phase 2 trial to evaluate the efficacy and safety of orally-administered LEO 152020 tablets compared with placebo tablets for up to 16 weeks of treatment in adults with moderate to severe atopic dermatitis (eczema)Atopic Dermatitis (AD)MedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858EUCTR2020-004561-39-DEEO Pharma A/S224
进行中（未招募）
1 期
Efficacy and safety of different dose regimens of LEO 152020 tablets for the treatment of adults with moderate to severe atopic dermatitis up to 16 weeksAtopic Dermatitis (AD)MedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858EUCTR2020-004561-39-CZEO Pharma A/S224
进行中（未招募）
1 期
A phase 2 trial to evaluate the efficacy and safety of orally-administered LEO 152020 tablets compared with placebo tablets for up to 16 weeks of treatment in adults with moderate to severe atopic dermatitis (eczema)Atopic Dermatitis (AD)MedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858EUCTR2020-004561-39-ESEO Pharma A/S224
已完成
2 期
Efficacy and Safety of LEO 152020 Tablets for the Treatment of Adults With Moderate to Severe Atopic DermatitisAtopic DermatitisJPRN-jRCT2031210485Kikuchi Aki224